Study of Intrathecal Magnesium Sulphate as an Adjunct to Bupivacaine for Subarachnoid Block in Infraumbilical Surgeries - A Randomised Double-Blind Study

Amitha P. Rao¹, Krishna Sagar Sriram²

¹Department of Anaesthesia, District Hospital, Haveri, Karnataka, India. ²Department of Anaesthesia, Balaji Multispeciality Hospital, Hindupur, Andhra Pradesh, India.

ABSTRACT

BACKGROUND
To improve the quality and duration of subarachnoid block various adjuncts have been used. But they exhibit side effects like nausea, vomiting, pruritis, respiratory depression, urinary retention and haemodynamic instability. Magnesium does not cause adverse effects when used as an adjuvant in therapeutic doses.

METHODS
This was a prospective, randomized, double blind, controlled study. 50 patients belonging to ASA physical status I and II posted for infraumbilical surgery were randomized into two groups. Group I patients received Inj. bupivacaine 0.5% heavy 2.5 mL (12.5 mg) with Inj. normal saline 0.2 mL intrathecally. Group II patients received Inj. bupivacaine 0.5% heavy 2.5 mL (12.5 mg) with Inj. magnesium sulphate 25% 0.2 mL (50 mg) intrathecally. The onset and duration of sensory blockade, the onset and duration of motor blockade, haemodynamic parameters, Ramsay sedation score and Visual Analogue Scale were assessed. Rescue analgesia was given when VAS score was >3. Statistical analysis was performed by student’s t-test for nominal data, Chi-square test or Fisher's exact probability test for categorical data.

RESULTS
When 50 mg of magnesium sulphate was added intrathecally, the duration of motor blockade was prolonged (p value of <0.001); the onset of motor blockade was significantly slower, and the duration of analgesia was prolonged (p value <0.001). The prolonged analgesia in magnesium sulphate group was accompanied by an average 24-hour postoperative visual analogue scale of 1 to 2 when compared to 3 to 4 in saline group (p ≤ 0.001).

CONCLUSIONS
Intrathecal magnesium sulphate as an adjunct to bupivacaine in spinal anaesthesia prolongs the duration of spinal anaesthesia and postoperative analgesia, without adverse effects.

KEYWORDS
Subarachnoid Block, Intrathecal Adjuvant, Magnesium Sulphate, Analgesia, NMDA Receptor
Spinal anaesthesia or subarachnoid block is the most commonly practiced anaesthetic procedure in our day to day anaesthesia routine. Local anaesthetics like lignocaine, bupivacaine or ropivacaine given intrathecally for spinal anaesthesia alone are associated with a relatively short duration of action and do not cover the postoperative analgesic needs. Various additives have been used to improve the characteristics of subarachnoid block like opioids, clonidine, dexmedetomidine, ketamine, neostigmine, epinephrine, magnesium sulphate and other agents. Magnesium sulphate is a non-competitive NMDA (n-methyl D-aspartate) receptor antagonist. NMDA receptor antagonists prevent the induction of central sensitization attributed to peripheral nociceptive stimulation. Intrathecal magnesium sulphate potentiates morphine antinociception at the spinal level in naive rats. It increased the peak effect and area under the analgesic curve in morphine rats. Intrathecal magnesium sulphate potentiates spinal anaesthesia by a localized action on spinal nociceptive pathways. It reduces the activation of C-fibres by inhibiting slow excitatory post synaptic currents produced by NMDA receptor activation. The binding and dissociation of non-competitive NMDA receptor antagonists is relatively slow, which may prolong anaesthesia into the postoperative period. When magnesium sulphate was administered intrathecally, the time of maximum sensory block, time of onset of motor block and time for analgesic request were prolonged. Postoperative pain is associated with neuroendocrine responses, catecholamine release and increased morbidity. Intrathecal magnesium reduced morphine consumption at 24 hours postoperatively, and modestly reduced early postoperative pain scores without increasing risk of hypotension, bradycardia or sedation. A limitation to the parenteral use of magnesium for modulation of antinociception via NMDA channel antagonism is insufficient blood-brain barrier penetration to achieve effective concentration. Magnesium in a dose of 50 mg to 100 mg with local anaesthetic for spinal anaesthesia has been used in various studies. 50% of 100 mg intrathecal magnesium sulphate did not have more desirable effect than 75 mg and 100 mg of intrathecal magnesium sulphate. Hence in our study, we used a dose of 50 mg magnesium sulphate intrathecally which was the minimum dose to prolong analgesia. The primary objective was to study the duration of spinal anaesthesia and time for rescue analgesic with the use of intrathecal magnesium sulphate as an adjunct to 0.5% hyperbaric bupivacaine. The secondary objective was to observe perioperative side effects following magnesium administration.

We performed a prospective, randomized, double blind study. Randomization was done using numbers generated from www.random.org. 25 patients were included in each group to detect a 10% difference in the duration of spinal anaesthesia, at a confidence interval of 95% and keeping the power of study 80%.

**Inclusion Criteria**

The inclusion criteria were patients aged 18 to 60 years, ASA physical status I and II, body mass index of 18.5 to 24.9, posted for elective infraumbilical surgery.

**Exclusion Criteria**

The exclusion criteria were patients with coagulation disorders, infection at site of lumbar puncture, neurologic and psychiatric disturbances, uncontrolled diabetes, hypertension, significant coexisting diseases, patients with opioid or analgesic abuse, history of hypersensitivity to magnesium, neuropathy, patients who refused to give consent.

After obtaining informed written consent from patients, 50 patients posted for infraumbilical surgery were randomly divided into two groups. Group I patients received Inj. bupivacaine 0.5% heavy 2.5 mL (12.5 mg) with Inj. normal saline 0.2 mL intrathecally. Group II patients received Inj. bupivacaine 0.5% heavy 2.5 mL (12.5 mg) with Inj. magnesium sulphate (preservative free) 25% 0.2 mL (50 mg) intrathecally. The study drug was measured using an insulin syringe.

After shifting the patient to operation theatre, intravenous (IV) line was secure. The patients were preloaded with 10 to 15 mL/Kg body weight of Ringer's lactate solution 15 to 20 minutes before the administration of spinal anaesthesia. Monitors like pulse oximeter, non-invasive blood pressure (NIBP) and electrocardiography (ECG) were connected. Baseline parameters were recorded. Patients were premedicated with Inj. midazolam 1 mg IV. The study drug syringes were prepared by a senior anaesthesiologist who was further not involved in the study. Patients and the anaesthesia provider were not aware of the study drug. Patients were randomly assigned to group I and group II. Under aseptic precautions, lumbar puncture was performed with the patient in lateral position at L3 - L4 interspace by midline approach using 25-gauge Quincke’s needle and the respective study drug was administered. Patients were positioned in supine position.

The anaesthesiologist recorded the intraoperative parameters. Sensory blockade was noted by loss of sensation to temperature bilaterally along midclavicular line using a spirit swab. Motor blockade was noted by using the Bromage scale (Bromage 0 - Patient able to move hip, knee and ankle; Bromage 1 - Patient able to move hip and knee, but able to move ankle, Bromage 2 - patient not able to move hip, but able to move knee and ankle; Bromage 3 - Patient not able to move hip, knee and ankle). Time for onset of sensory blockade, time for onset of motor blockade, maximal height of sensory blockade, total duration of sensory blockade, total duration of motor blockade were
noted. Oxygen saturation (SpO\textsubscript{2}), heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), electrocardiography (ECG), respiratory rate (RR), Ramsay sedation score (RSS) and any side effects were recorded at the baseline, at 0, 1, 2, 5 minutes of subarachnoid block and 5 minutes thereafter until 1 hour, 15 minutes thereafter until the end of surgery. If SBP was ≤90 mmHg or if MAP was <60 mmHg, Inj. mephentermine 6 mg IV stat was administered. If HR was <50 beats per minute, Inj. Atropine 0.6 mg IV stat was administered.

The onset of sensory blockade is defined as time for T\textsubscript{10} dermatomal blockade. The duration of sensory blockade is defined as time for two dermatomal segments regression (from the highest dermatomal blockade). The time for onset of motor blockade was when Bromage score was 3. The duration of motor blockade is defined as time for recovery to Bromage 0. Duration of analgesia is the time from the administration of subarachnoid block to first rescue analgesics.

Ramsay sedation score, visual analogue scale (VAS) were assessed postoperatively immediately, 30 minutes, 1 hour, 1½ hour, 2-hour, 6-hour, 12-hour and 24-hour. Side effects like nausea, vomiting, respiratory depression, sedation were noted. Time for request of first analgesic was noted and rescue analgesic was given as Inj. diclofenac 75 mg intramuscular.

Features of magnesium toxicity like bradycardia, hypotension, arrhythmias, respiratory distress, drowsiness, hyperexcitability, decreased urine output (<0.5 mL/Kg/hour) and others if any were noted.

**Statistical Analysis**

After completing the study, our observations were tabulated and analysed by student’s t-test for nominal data; by Chi-square test or Fisher’s exact probability test for categorical data. A p-value of less than 0.05 was considered statistically significant. Version of software used was SAS 9.2, SPSS 15. In order to keep power of the test 80%, a sample size of 25 patients was decided.

## RESULTS

25 patients were enrolled in each group. The age, sex, weight, BMI, ASA physical status, type of surgery and duration of surgery were comparable in the two groups.

| Parameters                        | Group I (n=25) | Group II (n=25) | P Value |
|-----------------------------------|---------------|----------------|---------|
| Onset of sensory blockade (seconds) | 168 ± 71.4   | 124.8 ± 62.2  | 0.027   |
| Onset of motor blockade (seconds)  | 245.71 ± 110.47 | 379.2 ± 241.69 | 0.016   |
| Duration of motor block (minutes) | 136.8 ± 37.82 | 215.4 ± 49.11 | <0.001  |
| Time for rescue analgesia (minutes) | 107.2 ± 22.67 | 238.2 ± 116.98 | <0.001  |

**Table 2. Characteristics of Sensory and Motor Blockade**

Our observation was that the onset of sensory blockade was significantly faster in magnesium group when compared to saline group (p <0.05). The onset of motor blockade was significantly slower in magnesium group with p value <0.001. Duration of sensory and motor blockade was significantly longer in magnesium group with p value <0.001. The time for first analgesic request was significantly prolonged with the addition of intrathecal magnesium with p value <0.001. The mean time for rescue analgesic was 136.80 ± 37.83 min in saline group versus 228.20 ± 101.56 min in magnesium group.
The average visual analogue scale (VAS) in first 24 hours of postoperative period was 1 to 2 in group II versus 3 to 4 in group I. The p value was highly significant at all intervals: ≤0.001. There was no difference in the haemodynamic parameters among the two groups. The sedation scores are comparable among the two groups. Sedation does not occur with the addition of magnesium sulphate in a dose of 50 mg.

Adverse effects of magnesium like bradycardia, hypotension, arrhythmias, respiratory distress, drowsiness, decreased urine output were absent in both the groups.

### DISCUSSION

NMDA receptor with second messenger effectors plays a role in the development of chronic pain after an acute injury. Magnesium ion blocks NMDA receptor associated channels in a voltage dependent manner. Noxious stimulation leads to the release of neurotransmitters like glutamate and aspartate, which bind to various subclasses of excitatory amino acid receptors including the N-methyl d-aspartate (NMDA) receptor. Activation of NMDA receptors leads to calcium and sodium influx into the cell, with an efflux of potassium and initiation of central sensitization and wind-up phenomena and long-term synaptic plasticity. Magnesium is a natural physiological calcium antagonist and its antinociceptive effect is regulated by calcium influx into the cell. This prevents the induction of central sensitization. Magnesium improves recovery from spinal cord ischemia when administered intrathecally in rat and dog models. Ischemic injury appears to be related to increased levels of excitatory amino acids and magnesium blocks this dorsal horn NMDA receptor activation. Intrathecal magnesium was first used in humans in 1906 in which 1000-2000 mg of intrathecal magnesium produced spinal anaesthesia with profound sensory and motor block but without any permanent untoward effect. Lejuste described an inadvertent intrathecal injection of magnesium with profound neurologic effects. Intrathecal magnesium is well tolerated in doses of 1000-2000 mg. Intrathecal magnesium concentrations were fairly constant at 50-200 mg/l in this study. Magnesium improves recovery from spinal cord ischemia when administered intrathecally in rat and dog models.

Intravenous administration of magnesium, even at high doses undergo limited transfer across the blood-brain barrier. The cerebrospinal fluid (CSF) concentration of magnesium does not vary with variation in plasma concentration of magnesium.

Intrathecal magnesium was first used in humans in 1906 in which 1000-2000 mg of intrathecal magnesium produced spinal anaesthesia with profound sensory and motor block but without any permanent untoward effect. Lejuste described an inadvertent intrathecal injection of magnesium with profound neurologic effects. Intrathecal magnesium is well tolerated in doses of 1000-2000 mg. Intrathecal magnesium concentrations were fairly constant at 50-200 mg/l in this study. Magnesium improves recovery from spinal cord ischemia when administered intrathecally in rat and dog models.

Intravenous administration of magnesium, even at high doses undergo limited transfer across the blood-brain barrier. The cerebrospinal fluid (CSF) concentration of magnesium does not vary with variation in plasma concentration of magnesium.
1000 mg of magnesium that produced a dense motor block followed by a complete resolution within 90 minutes and no neurological deficit at long term follow-up.23 Buvanendran et al. were first to perform study on 50 mg of intrathecal magnesium used as adjuvant with intrathecal fentanyl in labouring parturients and its effect on prolonging duration of analgesia, compared to plain intrathecal fentanyl.24

Our results are comparable to a study by Binish K et al. who observed decreased postoperative analgesic consumption with the use of 50 mg and 75 mg of intrathecal magnesium sulphate to bupivacaine in lower limb orthopaedic surgeries.19 Paul et al.,25 Jaiswal R et al.26 too observed similar results in lower limb orthopaedic surgeries. Jabalameli M et al. conducted study by adding 50, 75, 100 mg magnesium sulphate as an adjuvant for spinal anaesthesia in caesarean section.20 There was a delay in sensory and motor blockade in all the groups. Intraoperative side effects like hypotension, nausea and vomiting were more when 100 mg of magnesium was used. 75 mg of the drug was enough to achieve the desired effect without increasing major side effects. In many studies performed by Khemaikhem et al.,36 Ozalevi M et al.,37 Malleeswaran S et al.,38 Bidyut and Kumar39 using magnesium sulphate as an intrathecal adjunct during caesarean section, they noted prolongation of sensory and motor blockade, prolongation in the time of analgesia request, reduced postoperative analgesic requirement without additional side effects; and the results were similar to the results of our study.

In our study the onset of motor blockade was delayed in magnesium group. This was similar to the results of study conducted by Arora B and co-workers who conducted study with intrathecal magnesium sulphate as adjuvant for spinal anaesthesia for caesarean section in pre-eclampsia.10

**Limitation**

We could not obtain serum magnesium levels of our patients.

**CONCLUSIONS**

Intrathecal magnesium sulphate added to bupivacaine prolongs the duration of spinal anaesthesia and duration of postoperative analgesia without haemodynamic instability or any other adverse effects. Magnesium sulphate can be used as an efficient and safe intrathecal adjuvant to reduce postoperative analgesic requirements and to minimize use of opioids, as well as opioid related undesirable side effects.

Financial or Other Competing Interests: None.

**REFERENCES**

[1] Brown DL. Spinal epidural and caudal anaesthesia. In: Miller RD, Eriksson LI, Fleisher LA, et al, eds. Miller's anesthesia. Vol. 2. 7th edn. Philadelphia, PA: Elsevier Churchill Livingstone 2010: p. 1624.

[2] Unlugenc H, Ozalevi M, Gunus Y, et al. A double-blind comparison of intrathecal S (+) ketamine and fentanyl combined with bupivacaine 0.5% for Caesarean delivery. Eur J Anaesthesiol 2006;23(12):1018-1024.

[3] Sethi BS, Samuel M, Sreevastva D. Efficacy of analgesic effects of low dose intrathecal clonidine as an adjuvant to bupivacaine. Indian J Anaesth 2007;51(5):415.

[4] Gupta R, Bogra J, Verma R, et al. Dexmedetomidine as an intrathecal adjuvant for postoperative analgesia. Indian J Anaesth 2011;55(4):347-351.

[5] Nelson KE, D’Angelo R, Foss ML, et al. Intrathecal neostigmine and sufentanil for early labor analgesia. Anesthesiology 1999;91(5):1293-1298.

[6] Gurbet A, Turker G, Kose DO, et al. Intrathecal epinephrine in combined spinal-epidural analgesia for labor: dose response relationship for epinephrine added to a local anesthetic-opioid combination. Int J Obstet Anesth 2005;14(2):121-125.

[7] Marzouk S, El-Hardy NA, Lofty M, et al. The effect of three different doses of intrathecal magnesium sulphate on spinal opioid analgesia. Eg J Anaesth 2003;19:405-409.

[8] Dube L, Granry JC. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: a review. Can J Anaesth 2003;50(7):732-746.

[9] Guler A, Satlimis T, Akini SB, et al. Magnesium sulphate pretreatment reduces myoclonus after etomidate. Anesth Analg 2005;101(3):705-709.

[10] Ascher P, Nowal L. Electrophysiological studies of NMDA receptors. Trends Neurosciences 1987;10(7):284-288.

[11] Koijn JS, McCarthy RJ, Von Roenn N, et al. Magnesium sulphate potentiates morphine antinociception at the spinal level. Anesth Analg 2000;90(4):913-917.

[12] Unlugenc H, Ozalevi M, Gundz M, et al. Comparison of intrathecal magnesium, fentanyl or placebo combined with bupivacaine 0.5% for parturients undergoing elective cesarean delivery. Acta Anaesthesiol Scand 2009;53(3):346-353.

[13] Bonhaus DW, McNamara JO. N-methyl-D-aspartate receptor regulation of uncompetitive antagonist binding in rat brain membranes: kinetic analysis. Mol Pharmacol 1988;34(3):250-255.

[14] Hwang JY, Na HS, Jeon YT, et al. I.V. infusion of magnesium sulphate during spinal anaesthesia improves postoperative analgesia. Br J Anaesth 2010;104(1):89-93.

[15] Rosaeg OP, Lui AC, Cicutti NJ, et al. Perioperative multimodal pain therapy for caesarean section: analgesia and fitness for discharge. Can J Anaesth 1997;44(8):803-809.

[16] Stoebling RK, Hillier SC. Centrally Acting nonopioid analgesics. In: Elsharkawy H, Naguib MA, eds. Stoebling’s pharmacology & physiology in anaesthetic practice. 5th edn. Philadelphia: Lippincott Williams & Wilkins 2006:164-165.
Comparison of analgesic requirements.

Anesth Analg 1993;77(2):362-379.

Koinig H, Wallner T, Marhofer P, et al. Magnesium sulphate reduces intra and postoperative analgesic requirement. Anesth Analg 1998;87(1):206-210.

Campora E, Merlini I, Pace M, et al. The incidence of narcotic induced emesis. J Pain Symptom Manage 1991;6(7):428-430.

McKee JA, Brewer RP, Macy GE, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulphate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med 2005;33(3):661-666.

Ko SH, Lim HR, Kim DC, et al. Magnesium sulphate does not reduce postoperative analgesic requirements. Anaesthesiology 2001;95(3):640-646.

Houbold HA, Meltzer SJ. Spinal anesthesia by magnesium sulphate. A report of seven operations performed under its influence. J Am Med Assoc 1906;46(9):647-650.

Lejuste MI. Inadvertent intrathecal administration of magnesium sulfate. S Afr Med J 1985;68(6):367-368.

Buvanendran A, McCarthy RJ, Kroin JS, et al. Intrathecal magnesium prolongs fentanyl analgesia: a prospective, randomised, controlled trial. Anesth Analg 2002;95(3):661-666.

Jaiswal R, Bansal T, Kothari S, et al. The effect of adding magnesium sulphate to bupivacaine for spinal anaesthesia: a randomized double-blind trial in patients undergoing lower limb orthopedic surgery. Int J Pharm Sci 2013;5(4):179-182.

Khemakhem K, Smyoth M, Ghrab B, et al. The effect of adding intrathecal magnesium sulphate to morphine for postoperative analgesia after caesarean section: A-708. Eur J Anesth 2006;23(Suppl 37):183-184.

Ozalevli M, Cetin TO, Unilungc H, et al. The effect of adding intrathecal magnesium sulphate to bupivacaine fentanyl spinal anaesthesia. Acta Anaesthesiol Scand 2005;49(10):1514-159.

Malleeswaran S, Panda N, Mathew P, et al. A Randomised study of magnesium sulphate as an adjuvant to intrathecal bupivacaine in patients with mild preeclampsia undergoing caesarean section. Int J Obstet Anest 2010;19(2):161-166.

Bidyut N, Kumar S. Intrathecal magnesium improves postoperative analgesia in pre eclamptics undergoing caesarean section. Proceedings of the Annual Meeting of the American Society of Anaesthesiologists 2009.